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Susac’s Syndrome (SS) is an autoimmune endotheliopathy of cerebral, retinal and cochlear arterioles. We report of
an HIV-infected woman who developed a first SS episode following a spontaneous reduction of plasma viral load
and several relapses six years later, following initiation of combined antiretroviral therapy (cART). Corticosteroids and
intravenous immunoglobulins alone did not control the disease, which improved after combined treatment with
acyclovir and ganciclovir. SS onset in HIV infection and relapses during cART-induced immune reconstitution are
consistent with the dysimmune nature of the disease. The response to anti-herpes drugs suggests a viral contribute
in this case of SS.Introduction
Susac’s syndrome (SS) is a rare autoimmune micro-
angiopathic disorder, affecting precapillary arterioles of the
brain, retina and cochlea [1]. Until now, approximately 200
cases have been reported [2], mainly in women. Headache,
focal neurological signs, deafness and ocular symptoms are
the most common clinical manifestations, but do not
necessary occur simultaneously. SS is almost never fatal [3],
however it is characterized by spontaneous remissions and
relapses that can only partially be controlled or delayed by
immunosuppressive drugs and often lead to irreversible
neurological sequelae and poor quality of life.
We here describe a case of SS in an HIV-infected woman,
who developed a first episode following a spontaneous
decrease of plasma viral load, and several relapses 6
years later, following introduction of combined anti-
retroviral therapy (cART), as likely expression of an
immune reconstitution inflammatory syndrome (IRIS).
Notably, the neurological picture was not controlled
by corticosteroids and intravenous immunoglobulins
alone, but only when acyclovir and ganciclovir were
administered concomitantly, suggesting a possible role of
herpes viruses in SS pathogenesis in this case.* Correspondence: ferretti.francesca@hsr.it
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In September 2002, a 42 year-old woman with a 15-year
history of untreated HIV-1 and hepatitis C virus infection
was admitted to our Infectious Diseases Department with
headache, facial paresthesias, amaurosis, hemianopsia, tin-
nitus and vertigo (Table 1). Blood CD4+ cells were 355/μL
and plasma HIV-RNA level had unexplainably dropped
from 270,000 to 2000 copies/mL in the previous 9 months,
in absence of ART. Brain magnetic resonance imaging
(MRI) showed T2-hyperintense lesions in the basal ganglia,
bilateral subcortical and deep cerebral white matter and
medium-posterior corpus callosum, some of which were
gadolinium enhancing (images not available). Cerebro-
spinal fluid (CSF) analysis showed only mild pleocytosis
and protein increase, fundus oculi examination a retinal
vascular occlusion in the superior temporal regions, audio-
metric examination a neuro-sensorial left hypoacusia.
The diagnosis was of cerebral vasculitis and suspected
cytomegalovirus (CMV) retinopathy. Intravenous (i.v.)
methylprednisolone and gancyclovir were administered
(Table 1), followed by clinical resolution.
The patient remained asymptomatic for six years, with
MRI showing persistence of inactive brain lesions. In
January 2008 she started treatment with tenofovir,
emtricitabine and unboosted atazanavir and in 4 weeks
CD4+ cells increased from 202 to 260/μL and HIV-RNA
dropped from 13,000 c/mL to undetectable (< 50 c/mL).
In March 2008, after 6 weeks of cART, she presentedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypoacusia. VEP, AEP: normal
None IV MEP 20 mg bid (3 days).
























EEG: focal slow abnormal
activity in the left temporal region
cART: TDF, FTC,
ATV (6 weeks)
Oral PDN 50 mg qd
(5 days), then 25 mg qd



















Visual field: central scotoma of right
eye, arcuate scotoma in the superior
and inferior field of left eye. FO: right
retinal vasculopathy. RFA: acute bilateral
retinal vasculitis with reduced perfusion.
VEP: absent response of right eye,
reduced response of left eye; AEP:
mixed bilateral hypoacusia.
None IV MEP 1 g qd (5 days),
then oral PDN 50 mg qd





























IV MEP 1 g qd (6 days),










brain stem) (Figure 1c)
cART: TDF, FTC,
ATV (6 weeks).
Oral PDN 75 mg qd
(5 days)
IV Ig 15.5 g qd (5 days).



























CSF cART: TDF, FTC,
ATV (8 weeks).
IV MEP 40 mg
bid (6 days)
IV MEP 1 g qd (3 days),
then oral PDN 150 mg qd,
tapered to 5 mg in 16 weeks.
IV GCV 5 mg/Kg bid (14 days),
then oral V-GCV 450 mg qd
(4 weeks). IV ACV 15 mg/Kg
tid (14 days), then oral ACV















IV MEP 1 g qd (3 days).
IV ACV 15 mg/Kg tid
(14 days), then oral





* Microbiology: microscopic and culture for bacteria, mycobacteria and fungi; ** Viral genomes: DNA of herpes simplex virus type 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr
virus, JC virus.
VL HIV-RNA, VDRL Venereal disease research laboratory test, TPHA Treponema pallidum hemagglutination, neg Negative, CSF Cerebrospinal fluid, p-ANCA Perinuclear anti-neutrophil cytoplasmic antibodies, c-ANCA
Cytoplasmic anti-neutrophil cytoplasmic antibodies, anti-beta 2-gp Anti beta-2 glycoprotein, LA Lupus anticoagulant antibodies, ANA Antinuclear antibodies, N.A. Not available, MRI Magnetic resonance imaging,
Gd Gadolinium, FO Fundus oculi, RFA Retinal fluorangiography, VEP Visual evoked potentials, AEP Auditory evoked potential, EEG Electroencephalogram, cART Combination antiretroviral therapy, TDF Tenofovir,


















Figure 1 (See legend on next page.)
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Figure 1 Brain magnetic resonance imaging: axial FLAIR (first column), axial Gd -T1 (second column), sagittal T2 (third column: A, B, E),
coronal FLAIR (C) or coronal Gd-T1 (D). A. March 14th, 2008 (first relapse): T2/FLAIR hyperintense non-enhancing lesions of centra semiovalia
(arrow) and corpus callosum (arrow) white matter. B. April 1st, 2008 (first relapse, follow-up; diagnosis of SS): increased number and intensity of
the T2/FLAIR hyperintense non-enhancing lesions of brain white matter, corpus callosum (arrow), also extending to cerebellum (not shown).
C. May 15th, 2008 (third relapse): further increase of lesion number and intensity, some of the lesions are now enhancing (arrow). D. November
25th, 2008 (fourth relapse): stabilization of the supratentorial lesions, but new multiple contrast-enhancing brain (arrow) and cerebellar lesions
(arrows). E. September 6th, 2012 (long-term follow-up): no evidence of disease activity with ensuing brain atrophy, as shown by dilatation of
cortical sulci and loss of brain volumes, including at the corpus callosum (arrow).
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increased T2 hyperintensity of old lesions and one
new right frontal lesion, without contrast enhancement
(Figure 1a). CNS-IRIS was suspected, patient was treated
with oral prednisone and self-suspended cART. After three
weeks, however, she was admitted to our department for
worsening of previous neurological symptoms with new
onset of hemiparesis and hypoacusia. Brain MRI showed
further increased hyperintensity of old lesions and new
non-enhancing T2 hyperintense cerebral and cerebellar
lesions (Figure 1b). Fundus oculi examination showed
right retinal vasculitis characterized by bilateral arteri-
olar wall hyperfluorescence and reduced perfusion at
fluorangiography. Auditive evoked potentials confirmed
the hypoacusia. SS was diagnosed based on current and
retrospectively examined clinical and radiological findings
along with exclusion of other central nervous system
(CNS) diseases. The patient received high dose i.v. methyl-
prednisolone with partial remission of symptoms and was
discharged with maintenance oral prednisone. cART
was restarted after four-weeks withdrawal.
In April 2008, three weeks after discharge, the patient
was readmitted for new neurological symptoms and
contrast-enhancing brain lesions at MRI (second relapse).
She received high dose i.v. methylprednisolone, tapered
with oral prednisone, followed by mild clinical improve-
ment. A third relapse with new MRI contrast-enhancing
lesions occurred in May 2008, while patient was still on
maintenance oral prednisone (Figure 1c). She received i.v.
immunoglobulin followed by 40 mg bid of i.v. methyl-
prednisolone, with no improvement. High dose i.v.
methylprednisolone was then started. I.v. gancyclovir
and acyclovir were also administered for the presence of
CMV pp65 antigen in plasma (5 nuclei) and suspecting a
reactivation of a viral infection of the CNS, in view of the
response to gancyclovir during the first episode in 2002.
Patient conditions improved substantially and she was
discharged with oral maintenance prednisone, acyclovir and
valgancyclovir. Acyclovir was continued for 3 weeks and
valganciclovir was stopped after 4 weeks for hematologic
toxicity. In August 2008 cART was switched to lamivudine,
tenofovir and abacavir. A fourth relapse occurred seven
months later, with new MRI contrast enhancing cerebral
and cerebellar lesions (Figure 1d). Patient was treated withi.v. methylprednisolone and i.v. acyclovir for 14 days,
followed by clinical and MRI improvement with no
further relapses.
During the following years the patient continued cART
and oral prednisone maintenance at 2.5-5 mg per day,
increased to 12.5-25 mg for short periods, for worsening of
vertigo. She experienced no new neurological episodes, but
was left with severe neurological sequelae, iatrogenic
diabetes and severe osteoporosis with vertebral fractures.
At last visit in January 2013 the patient had mild cognitive
impairment by neuropsychological evaluation, walked with
a cane and suffered from severe visual and earing loss.
There was no evidence of disease activity at MRI (Figure 1e),
CD4+ were 574 cells/μL and HIV-RNA <50 c/mL.
Discussion
This is, to our knowledge, the first case of SS described in
an HIV-infected person. Our patient met all the diagnostic
criteria for SS, i.e., MRI findings of corpus callosum
microinfarctions, leptomeningeal enhancement and grey
matter involvement, evidence of branch retinal artery
occlusion at retinal fluorangiography and abnormal
brainstem auditory evoked potentials [1]. In agreement
with what often reported [4], diagnosis was achieved only
years after onset, when the classical triad of cerebral,
ocular and auditory involvement was documented, along
with exclusion of other etiologies.
In our case, symptoms occurred in the peculiar
context of immune reconstitution, which was apparently
spontaneous at the onset of SS and associated with
cART in the subsequent relapses, providing the criteria
for IRIS [5]. IRIS consists of a broad spectrum of inflamma-
tory diseases that present after starting an effective cART,
leading to CD4+ cells increase and, more importantly,
plasma HIV-RNA reduction. [6] IRIS reflects a paradoxycal
inflammatory response to opportunistic pathogens, such as
Cryptococcus spp [7], mycobacteria [8], JC virus [9], or also
to auto-antigens [10,11]. Indeed, autoimmune diseases like
Graves thyroiditis, pulmunary sarcoidosis, rheumatoid
arthritis, systemic lupus erythematosus and polymiositis
have been reported as IRIS manifestations [10]. The recent
finding of anti-endothelium cell autoantibodies in some SS
patients [12] and the usually good response to immunosup-
pressive therapy support the autoimmune pathogenesis of
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an additional manifestation of “autoimmune IRIS”.
Our patient did not show a long-lasting response to
high dose i.v. steroids or i.v. immunoglobulins alone
in three attempts (first and second relapses), whereas
a substantial and durable improvement was achieved
both times steroids were combined with antiviral
drugs, i.e., acyclovir, active on herpes simplex virus
type 1 and type 2 and varicella-zoster virus (VZV),
and gancyclovir, also active on CMV and Epstein-Barr
virus. It is known that the response to steroids in SS
can not persist over time [13] and that SS can be
characterized by spontaneous attenuation of the immuno-
pathological process [3]. However, the temporal relation-
ship between antiviral treatment and clinical improvement
was strong and consistent in our case, suggesting that
reactivation of an herpesvirus in the CNS might have
contributed to disease pathogenesis.
We did not find evidence of herpesviruses in CSF
(Table 1), but this does not exclude possible low level
replication in CNS tissue [14]. We can speculate on a
pathogenic model by which an herpesvirus reactivated
in the context of immune reconstitution and, by rep-
lication in vascular cells [15] and consequent expos-
ure of either viral or auto-antigens, lead to immune
mediated damage of cerebral vessels. According to
this model, antiviral therapy could have initially con-
tributed to switch off the inflammatory stimulus by
control of viral replication. A potential candidate herpes-
virus is VZV. VZV can cause direct damage of CNS
vessels of all calibres and indirect damage of CNS
cells [16] and it is a well known cause of CNS vascu-
litis and ocular infections in HIV-infected subjects
[17,18]. In addition, herpes zoster, resulting from per-
ipheral VZV reactivation, is a frequent IRIS manifest-
ation and cases of VZV CNS-IRIS have recently been
reported [19,20].
In conclusion, our case shows that SS may occur
within a dysimmune context that is possibly sustained
by HIV infection, cART-associated immune reconstitu-
tion, or both. The clinical and neuroradiological remission
observed when antiviral drugs were added to corticoste-
roids support a potential pathogenetic role of herpes virus
reactivations in SS in our case.Consent
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